Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,367
archived clinical trials in
High Blood Pressure (Hypertension)

A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated:  6/6/2013
GSK Investigational Site
7
mi
from 43215
Columbus, OH
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated: 6/6/2013
GSK Investigational Site
7
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated:  6/6/2013
GSK Investigational Site
2026
mi
from 43215
Portland, OR
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated: 6/6/2013
GSK Investigational Site
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated:  6/6/2013
GSK Investigational Site
414
mi
from 43215
Philadelphia, PA
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated: 6/6/2013
GSK Investigational Site
414
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated:  6/6/2013
GSK Investigational Site
165
mi
from 43215
Pittsburgh, PA
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated: 6/6/2013
GSK Investigational Site
165
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated:  6/6/2013
GSK Investigational Site
165
mi
from 43215
Pittsburgh, PA
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated: 6/6/2013
GSK Investigational Site
165
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated:  6/6/2013
GSK Investigational Site
619
mi
from 43215
Providence, RI
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated: 6/6/2013
GSK Investigational Site
619
mi
from 43215
Providence, RI
Click here to add this to my saved trials
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated:  6/6/2013
GSK Investigational Site
333
mi
from 43215
Nashville, TN
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated: 6/6/2013
GSK Investigational Site
333
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated:  6/6/2013
GSK Investigational Site
905
mi
from 43215
Dallas, TX
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated: 6/6/2013
GSK Investigational Site
905
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated:  6/6/2013
GSK Investigational Site
995
mi
from 43215
Houston, TX
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated: 6/6/2013
GSK Investigational Site
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated:  6/6/2013
GSK Investigational Site
1011
mi
from 43215
Temple, TX
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated: 6/6/2013
GSK Investigational Site
1011
mi
from 43215
Temple, TX
Click here to add this to my saved trials
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated:  6/6/2013
GSK Investigational Site
1514
mi
from 43215
Murray, UT
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated: 6/6/2013
GSK Investigational Site
1514
mi
from 43215
Murray, UT
Click here to add this to my saved trials
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated:  6/6/2013
GSK Investigational Site
344
mi
from 43215
Richmond, VA
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated: 6/6/2013
GSK Investigational Site
344
mi
from 43215
Richmond, VA
Click here to add this to my saved trials
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated:  6/6/2013
GSK Investigational Site
329
mi
from 43215
Milwaukee, WI
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated: 6/6/2013
GSK Investigational Site
329
mi
from 43215
Milwaukee, WI
Click here to add this to my saved trials
Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
A Phase II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost and Placebo in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  6/6/2013
Clinical Research Facility
2091
mi
from 43215
Santa Clara, CA
Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
A Phase II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost and Placebo in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 6/6/2013
Clinical Research Facility
2091
mi
from 43215
Santa Clara, CA
Click here to add this to my saved trials
Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
A Phase II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost and Placebo in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  6/6/2013
Clinical Research Facility
430
mi
from 43215
Decatur, GA
Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
A Phase II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost and Placebo in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 6/6/2013
Clinical Research Facility
430
mi
from 43215
Decatur, GA
Click here to add this to my saved trials
Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
A Phase II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost and Placebo in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  6/6/2013
Clinical Research Facility
627
mi
from 43215
St. Joseph, MO
Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
A Phase II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost and Placebo in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 6/6/2013
Clinical Research Facility
627
mi
from 43215
St. Joseph, MO
Click here to add this to my saved trials
Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
A Phase II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost and Placebo in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  6/6/2013
Clinical Research Facility
481
mi
from 43215
New York, NY
Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
A Phase II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost and Placebo in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 6/6/2013
Clinical Research Facility
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
A Phase II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost and Placebo in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  6/6/2013
Clinical Research Facility
127
mi
from 43215
Cleveland, OH
Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
A Phase II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost and Placebo in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 6/6/2013
Clinical Research Facility
127
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
A Phase II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost and Placebo in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  6/6/2013
Clinical Research Facility
910
mi
from 43215
Dallas, TX
Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
A Phase II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost and Placebo in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 6/6/2013
Clinical Research Facility
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
(-)-Epicatechin and Pulmonary Arterial Hypertension
An Open Label Pilot Study of Purified (-)-Epicatechin to Improve Hemodynamics in Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  6/14/2013
University of California at San Francisco (UCSF)
2109
mi
from 43215
San Francisco, CA
(-)-Epicatechin and Pulmonary Arterial Hypertension
An Open Label Pilot Study of Purified (-)-Epicatechin to Improve Hemodynamics in Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 6/14/2013
University of California at San Francisco (UCSF)
2109
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis
Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis
Status: Enrolling
Updated:  6/25/2013
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis
Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis
Status: Enrolling
Updated: 6/25/2013
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Hypotensive Effects of Conventional Dairy Products: Role of Arterial Stiffness
Hypotensive Effects of Conventional Dairy Products: Role of Arterial Stiffness
Status: Enrolling
Updated:  7/5/2013
The University of Texas at Austin, Cardiovascular Aging Research Laboratory
1065
mi
from 43215
Austin, TX
Hypotensive Effects of Conventional Dairy Products: Role of Arterial Stiffness
Hypotensive Effects of Conventional Dairy Products: Role of Arterial Stiffness
Status: Enrolling
Updated: 7/5/2013
The University of Texas at Austin, Cardiovascular Aging Research Laboratory
1065
mi
from 43215
Austin, TX
Click here to add this to my saved trials
Persistent Pulmonary Hypertension of the Newborn
Multicenter, Double-blind, Placebo-controlled, Randomized, Prospective Study of Bosentan as Adjunctive Therapy to Inhaled Nitric Oxide in the Management of Persistent Pulmonary Hypertension of the Newborn (PPHN)
Status: Enrolling
Updated:  7/9/2013
Lucile Salter Packard Children's Hospital, Pediatric Cardiology - Site 6017
2100
mi
from 43215
Palo Alto, CA
Persistent Pulmonary Hypertension of the Newborn
Multicenter, Double-blind, Placebo-controlled, Randomized, Prospective Study of Bosentan as Adjunctive Therapy to Inhaled Nitric Oxide in the Management of Persistent Pulmonary Hypertension of the Newborn (PPHN)
Status: Enrolling
Updated: 7/9/2013
Lucile Salter Packard Children's Hospital, Pediatric Cardiology - Site 6017
2100
mi
from 43215
Palo Alto, CA
Click here to add this to my saved trials
Persistent Pulmonary Hypertension of the Newborn
Multicenter, Double-blind, Placebo-controlled, Randomized, Prospective Study of Bosentan as Adjunctive Therapy to Inhaled Nitric Oxide in the Management of Persistent Pulmonary Hypertension of the Newborn (PPHN)
Status: Enrolling
Updated:  7/9/2013
Ann & Robert H. Lurie Children's Hospital of Chicago
274
mi
from 43215
Chicago, IL
Persistent Pulmonary Hypertension of the Newborn
Multicenter, Double-blind, Placebo-controlled, Randomized, Prospective Study of Bosentan as Adjunctive Therapy to Inhaled Nitric Oxide in the Management of Persistent Pulmonary Hypertension of the Newborn (PPHN)
Status: Enrolling
Updated: 7/9/2013
Ann & Robert H. Lurie Children's Hospital of Chicago
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Persistent Pulmonary Hypertension of the Newborn
Multicenter, Double-blind, Placebo-controlled, Randomized, Prospective Study of Bosentan as Adjunctive Therapy to Inhaled Nitric Oxide in the Management of Persistent Pulmonary Hypertension of the Newborn (PPHN)
Status: Enrolling
Updated:  7/9/2013
Advocate Hope Children's Hospital
275
mi
from 43215
Oak Lawn, IL
Persistent Pulmonary Hypertension of the Newborn
Multicenter, Double-blind, Placebo-controlled, Randomized, Prospective Study of Bosentan as Adjunctive Therapy to Inhaled Nitric Oxide in the Management of Persistent Pulmonary Hypertension of the Newborn (PPHN)
Status: Enrolling
Updated: 7/9/2013
Advocate Hope Children's Hospital
275
mi
from 43215
Oak Lawn, IL
Click here to add this to my saved trials
Persistent Pulmonary Hypertension of the Newborn
Multicenter, Double-blind, Placebo-controlled, Randomized, Prospective Study of Bosentan as Adjunctive Therapy to Inhaled Nitric Oxide in the Management of Persistent Pulmonary Hypertension of the Newborn (PPHN)
Status: Enrolling
Updated:  7/9/2013
Advocate Lutheran General Div. of Neonatal & Development Medicine - Site 6010
287
mi
from 43215
Park Ridge, IL
Persistent Pulmonary Hypertension of the Newborn
Multicenter, Double-blind, Placebo-controlled, Randomized, Prospective Study of Bosentan as Adjunctive Therapy to Inhaled Nitric Oxide in the Management of Persistent Pulmonary Hypertension of the Newborn (PPHN)
Status: Enrolling
Updated: 7/9/2013
Advocate Lutheran General Div. of Neonatal & Development Medicine - Site 6010
287
mi
from 43215
Park Ridge, IL
Click here to add this to my saved trials
Persistent Pulmonary Hypertension of the Newborn
Multicenter, Double-blind, Placebo-controlled, Randomized, Prospective Study of Bosentan as Adjunctive Therapy to Inhaled Nitric Oxide in the Management of Persistent Pulmonary Hypertension of the Newborn (PPHN)
Status: Enrolling
Updated:  7/9/2013
Medical University of South Carolina, Pediatric Cardiology - Site 6019
525
mi
from 43215
Charleston, SC
Persistent Pulmonary Hypertension of the Newborn
Multicenter, Double-blind, Placebo-controlled, Randomized, Prospective Study of Bosentan as Adjunctive Therapy to Inhaled Nitric Oxide in the Management of Persistent Pulmonary Hypertension of the Newborn (PPHN)
Status: Enrolling
Updated: 7/9/2013
Medical University of South Carolina, Pediatric Cardiology - Site 6019
525
mi
from 43215
Charleston, SC
Click here to add this to my saved trials
Blood Pressure Response to Sodium in the Diet
D1 and AT1 Receptor Interaction in Human Hypertension: Sodium Sensitivity of Blood Pressure
Status: Enrolling
Updated:  7/10/2013
University of Virginia
275
mi
from 43215
Charlottesville, VA
Blood Pressure Response to Sodium in the Diet
D1 and AT1 Receptor Interaction in Human Hypertension: Sodium Sensitivity of Blood Pressure
Status: Enrolling
Updated: 7/10/2013
University of Virginia
275
mi
from 43215
Charlottesville, VA
Click here to add this to my saved trials
Uric Acid and Hypertension in African Americans
Uric Acid and Hypertension in African Americans
Status: Enrolling
Updated:  7/18/2013
University of Florida
714
mi
from 43215
Gainesville, FL
Uric Acid and Hypertension in African Americans
Uric Acid and Hypertension in African Americans
Status: Enrolling
Updated: 7/18/2013
University of Florida
714
mi
from 43215
Gainesville, FL
Click here to add this to my saved trials
An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®
Assessing the Efficacy and Tolerability of TRAVATAN® Solution Without BAK, Containing Polyquad® Preservative (Travoprost 0.004%) Versus LUMIGAN® 0.01% Solution With BAK (Bimatoprost 0.01%) in Treatment Naïve Patients With Ocular Hypertension or Open Angle Glaucoma
Status: Enrolling
Updated:  7/18/2013
Contact Alcon Call Center at 1-888-451-3937 for Trial Locations
937
mi
from 43215
Fort Worth, TX
An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®
Assessing the Efficacy and Tolerability of TRAVATAN® Solution Without BAK, Containing Polyquad® Preservative (Travoprost 0.004%) Versus LUMIGAN® 0.01% Solution With BAK (Bimatoprost 0.01%) in Treatment Naïve Patients With Ocular Hypertension or Open Angle Glaucoma
Status: Enrolling
Updated: 7/18/2013
Contact Alcon Call Center at 1-888-451-3937 for Trial Locations
937
mi
from 43215
Fort Worth, TX
Click here to add this to my saved trials
A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
1963
mi
from 43215
Newport Beach, CA
A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
1963
mi
from 43215
Newport Beach, CA
Click here to add this to my saved trials
Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost
A Pilot, Single-Masked Study to Compare the Safety and Efficacy of ALZ-1101 (Latanoprost 0.005%/Dorzolamide 2.0%) to Latanoprost Ophthalmic Solution, 0.005% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension With Intraocular Pressure Inadequately Controlled By Latanoprost
Status: Enrolling
Updated:  7/22/2013
Sall Research Medical Center, Inc.
1968
mi
from 43215
Artesia, CA
Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost
A Pilot, Single-Masked Study to Compare the Safety and Efficacy of ALZ-1101 (Latanoprost 0.005%/Dorzolamide 2.0%) to Latanoprost Ophthalmic Solution, 0.005% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension With Intraocular Pressure Inadequately Controlled By Latanoprost
Status: Enrolling
Updated: 7/22/2013
Sall Research Medical Center, Inc.
1968
mi
from 43215
Artesia, CA
Click here to add this to my saved trials
Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost
A Pilot, Single-Masked Study to Compare the Safety and Efficacy of ALZ-1101 (Latanoprost 0.005%/Dorzolamide 2.0%) to Latanoprost Ophthalmic Solution, 0.005% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension With Intraocular Pressure Inadequately Controlled By Latanoprost
Status: Enrolling
Updated:  7/22/2013
Clayton Eye Center
446
mi
from 43215
Morrow, GA
Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost
A Pilot, Single-Masked Study to Compare the Safety and Efficacy of ALZ-1101 (Latanoprost 0.005%/Dorzolamide 2.0%) to Latanoprost Ophthalmic Solution, 0.005% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension With Intraocular Pressure Inadequately Controlled By Latanoprost
Status: Enrolling
Updated: 7/22/2013
Clayton Eye Center
446
mi
from 43215
Morrow, GA
Click here to add this to my saved trials
Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost
A Pilot, Single-Masked Study to Compare the Safety and Efficacy of ALZ-1101 (Latanoprost 0.005%/Dorzolamide 2.0%) to Latanoprost Ophthalmic Solution, 0.005% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension With Intraocular Pressure Inadequately Controlled By Latanoprost
Status: Enrolling
Updated:  7/22/2013
Texan Eye/Keystone Research
1062
mi
from 43215
Austin, TX
Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost
A Pilot, Single-Masked Study to Compare the Safety and Efficacy of ALZ-1101 (Latanoprost 0.005%/Dorzolamide 2.0%) to Latanoprost Ophthalmic Solution, 0.005% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension With Intraocular Pressure Inadequately Controlled By Latanoprost
Status: Enrolling
Updated: 7/22/2013
Texan Eye/Keystone Research
1062
mi
from 43215
Austin, TX
Click here to add this to my saved trials
Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost
A Pilot, Single-Masked Study to Compare the Safety and Efficacy of ALZ-1101 (Latanoprost 0.005%/Dorzolamide 2.0%) to Latanoprost Ophthalmic Solution, 0.005% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension With Intraocular Pressure Inadequately Controlled By Latanoprost
Status: Enrolling
Updated:  7/22/2013
Cataract & Glaucoma Center
1425
mi
from 43215
El Paso, TX
Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost
A Pilot, Single-Masked Study to Compare the Safety and Efficacy of ALZ-1101 (Latanoprost 0.005%/Dorzolamide 2.0%) to Latanoprost Ophthalmic Solution, 0.005% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension With Intraocular Pressure Inadequately Controlled By Latanoprost
Status: Enrolling
Updated: 7/22/2013
Cataract & Glaucoma Center
1425
mi
from 43215
El Paso, TX
Click here to add this to my saved trials
Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost
A Pilot, Single-Masked Study to Compare the Safety and Efficacy of ALZ-1101 (Latanoprost 0.005%/Dorzolamide 2.0%) to Latanoprost Ophthalmic Solution, 0.005% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension With Intraocular Pressure Inadequately Controlled By Latanoprost
Status: Enrolling
Updated:  7/22/2013
Medical Center Ophthalmology Associates
1138
mi
from 43215
San Antonio, TX
Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost
A Pilot, Single-Masked Study to Compare the Safety and Efficacy of ALZ-1101 (Latanoprost 0.005%/Dorzolamide 2.0%) to Latanoprost Ophthalmic Solution, 0.005% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension With Intraocular Pressure Inadequately Controlled By Latanoprost
Status: Enrolling
Updated: 7/22/2013
Medical Center Ophthalmology Associates
1138
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension
Phase 2 Trial for Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension
Status: Enrolling
Updated:  7/29/2013
Children's Hospital and Research Center Oakland
2098
mi
from 43215
Oakland, CA
Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension
Phase 2 Trial for Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension
Status: Enrolling
Updated: 7/29/2013
Children's Hospital and Research Center Oakland
2098
mi
from 43215
Oakland, CA
Click here to add this to my saved trials
Cognitive Dysfunction in Hypertensive Patients Having Spine Surgery
Cognitive Dysfunction in Hypertensive Patients Having Spine Surgery
Status: Enrolling
Updated:  7/29/2013
Columbia University
481
mi
from 43215
New York, NY
Cognitive Dysfunction in Hypertensive Patients Having Spine Surgery
Cognitive Dysfunction in Hypertensive Patients Having Spine Surgery
Status: Enrolling
Updated: 7/29/2013
Columbia University
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
Effects of High Fruit, Vegetable, and Dairy Intake on Plasma Lipids and Blood Pressure in Healthy Individuals
Effects of a Modified Lower Carbohydrate, Higher Fat DASH Diet Plan on Plasma Lipids, Lipoprotein Particle Size, and Blood Pressure in Healthy Adults
Status: Enrolling
Updated:  7/30/2013
Cholesterol Research Center, Children's Hospital Oakland Research Institute
2097
mi
from 43215
Berkeley, CA
Effects of High Fruit, Vegetable, and Dairy Intake on Plasma Lipids and Blood Pressure in Healthy Individuals
Effects of a Modified Lower Carbohydrate, Higher Fat DASH Diet Plan on Plasma Lipids, Lipoprotein Particle Size, and Blood Pressure in Healthy Adults
Status: Enrolling
Updated: 7/30/2013
Cholesterol Research Center, Children's Hospital Oakland Research Institute
2097
mi
from 43215
Berkeley, CA
Click here to add this to my saved trials
Effects of a Single OMT on Intraocular Pressure (IOP) in Ocular Hypertenive or Glaucoma Suspect Subjects
A Study of the Effects of a Single Osteopathic Manipulative Treatment (OMT) on Intraocular Pressure (IOP)in Un-medicated Confirmed Ocular Hypertensive (OHT) or Glaucoma Suspect Subjects
Status: Enrolling
Updated:  8/6/2013
UW Dept of Ophthalmology Clinic
392
mi
from 43215
Madison, WI
Effects of a Single OMT on Intraocular Pressure (IOP) in Ocular Hypertenive or Glaucoma Suspect Subjects
A Study of the Effects of a Single Osteopathic Manipulative Treatment (OMT) on Intraocular Pressure (IOP)in Un-medicated Confirmed Ocular Hypertensive (OHT) or Glaucoma Suspect Subjects
Status: Enrolling
Updated: 8/6/2013
UW Dept of Ophthalmology Clinic
392
mi
from 43215
Madison, WI
Click here to add this to my saved trials
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
Status: Enrolling
Updated:  8/16/2013
Johns Hopkins University
343
mi
from 43215
Baltimore, MD
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
Status: Enrolling
Updated: 8/16/2013
Johns Hopkins University
343
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan
Safety and Efficacy Trial Using Ambrisentan for Pulmonary Hypertension Associated With Congestive Heart Failure With Preserved Left Ventricular Ejection Fraction
Status: Enrolling
Updated:  9/16/2013
U.T. Southwestern Medical Center
910
mi
from 43215
Dallas, TX
Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan
Safety and Efficacy Trial Using Ambrisentan for Pulmonary Hypertension Associated With Congestive Heart Failure With Preserved Left Ventricular Ejection Fraction
Status: Enrolling
Updated: 9/16/2013
U.T. Southwestern Medical Center
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Remodulin® to Oral Treprostinil Transition
A Multicenter, Open-Label Study of the Safety and Tolerability of Transitioning From Remodulin® to Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/19/2013
Arizona Pulmonary Specialists, Ltd.
1661
mi
from 43215
Phoenix, AZ
Remodulin® to Oral Treprostinil Transition
A Multicenter, Open-Label Study of the Safety and Tolerability of Transitioning From Remodulin® to Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/19/2013
Arizona Pulmonary Specialists, Ltd.
1661
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Remodulin® to Oral Treprostinil Transition
A Multicenter, Open-Label Study of the Safety and Tolerability of Transitioning From Remodulin® to Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/19/2013
University of Arizona Clinical and Translational Science (CATS) Research Center
1639
mi
from 43215
Tucson, AZ
Remodulin® to Oral Treprostinil Transition
A Multicenter, Open-Label Study of the Safety and Tolerability of Transitioning From Remodulin® to Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/19/2013
University of Arizona Clinical and Translational Science (CATS) Research Center
1639
mi
from 43215
Tucson, AZ
Click here to add this to my saved trials
Remodulin® to Oral Treprostinil Transition
A Multicenter, Open-Label Study of the Safety and Tolerability of Transitioning From Remodulin® to Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/19/2013
Washington University School of Medicine
397
mi
from 43215
Saint Louis, MO
Remodulin® to Oral Treprostinil Transition
A Multicenter, Open-Label Study of the Safety and Tolerability of Transitioning From Remodulin® to Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/19/2013
Washington University School of Medicine
397
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Remodulin® to Oral Treprostinil Transition
A Multicenter, Open-Label Study of the Safety and Tolerability of Transitioning From Remodulin® to Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/19/2013
University of Rochester
354
mi
from 43215
Rochester, NY
Remodulin® to Oral Treprostinil Transition
A Multicenter, Open-Label Study of the Safety and Tolerability of Transitioning From Remodulin® to Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/19/2013
University of Rochester
354
mi
from 43215
Rochester, NY
Click here to add this to my saved trials
Remodulin® to Oral Treprostinil Transition
A Multicenter, Open-Label Study of the Safety and Tolerability of Transitioning From Remodulin® to Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/19/2013
University Hospitals of Cleveland
129
mi
from 43215
Cleveland, OH
Remodulin® to Oral Treprostinil Transition
A Multicenter, Open-Label Study of the Safety and Tolerability of Transitioning From Remodulin® to Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/19/2013
University Hospitals of Cleveland
129
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Remodulin® to Oral Treprostinil Transition
A Multicenter, Open-Label Study of the Safety and Tolerability of Transitioning From Remodulin® to Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/19/2013
Ohio State University
2
mi
from 43215
Columbus, OH
Remodulin® to Oral Treprostinil Transition
A Multicenter, Open-Label Study of the Safety and Tolerability of Transitioning From Remodulin® to Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/19/2013
Ohio State University
2
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Remodulin® to Oral Treprostinil Transition
A Multicenter, Open-Label Study of the Safety and Tolerability of Transitioning From Remodulin® to Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/19/2013
University of Pittsburgh Medical Center (UPMC)
165
mi
from 43215
Pittsburgh, PA
Remodulin® to Oral Treprostinil Transition
A Multicenter, Open-Label Study of the Safety and Tolerability of Transitioning From Remodulin® to Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/19/2013
University of Pittsburgh Medical Center (UPMC)
165
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching
An Open-Label Study to Explore the Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching When Used for Treatment of Group 1 Pulmonary Arterial Hypertension in Patients With Concomitant Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  9/26/2013
Cleveland Clinic Florida
971
mi
from 43215
Weston, FL
Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching
An Open-Label Study to Explore the Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching When Used for Treatment of Group 1 Pulmonary Arterial Hypertension in Patients With Concomitant Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 9/26/2013
Cleveland Clinic Florida
971
mi
from 43215
Weston, FL
Click here to add this to my saved trials